| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
17,274 |
13,632 |
$917K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
6,073 |
4,815 |
$232K |
| 99490 |
Ccm add 20min |
8,923 |
8,071 |
$223K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
1,567 |
1,355 |
$132K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
5,784 |
3,598 |
$103K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
3,351 |
2,187 |
$82K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
2,403 |
1,504 |
$66K |
| 99349 |
|
2,117 |
1,858 |
$56K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
1,687 |
1,058 |
$55K |
| Q3014 |
Telehealth originating site facility fee |
3,274 |
1,839 |
$45K |
| 99215 |
Prolong outpt/office vis |
383 |
299 |
$26K |
| 82075 |
|
4,900 |
2,875 |
$24K |
| 99336 |
|
398 |
286 |
$18K |
| 99385 |
|
305 |
222 |
$17K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,376 |
910 |
$16K |
| 99386 |
|
270 |
183 |
$15K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
533 |
454 |
$13K |
| 99407 |
|
737 |
625 |
$9K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
136 |
126 |
$8K |
| J2315 |
Injection, naltrexone, depot form, 1 mg |
293 |
199 |
$8K |
| 99344 |
|
245 |
212 |
$7K |
| 99205 |
Prolong outpt/office vis |
79 |
66 |
$7K |
| G0108 |
Diabetes outpatient self-management training services, individual, per 30 minutes |
688 |
583 |
$6K |
| 98968 |
|
270 |
212 |
$5K |
| G0444 |
Annual depression screening, 5 to 15 minutes |
433 |
379 |
$5K |
| 98967 |
|
371 |
290 |
$5K |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
89 |
63 |
$4K |
| G0442 |
Annual alcohol misuse screening, 5 to 15 minutes |
434 |
380 |
$4K |
| 80305 |
|
1,110 |
829 |
$4K |
| G0447 |
Face-to-face behavioral counseling for obesity, 15 minutes |
250 |
214 |
$4K |
| Q0091 |
Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory |
333 |
280 |
$4K |
| G0181 |
Physician or allowed practitioner supervision of a patient receiving medicare-covered services provided by a participating home health agency (patient not present) requiring complex and multidisciplinary care modalities involving regular physician or allowed practitioner development and/or revision of care plans |
2,077 |
1,997 |
$4K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
183 |
161 |
$2K |
| 99335 |
|
84 |
78 |
$2K |
| 36415 |
Collection of venous blood by venipuncture |
1,088 |
590 |
$1K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
51 |
48 |
$1K |
| 80306 |
|
1,191 |
560 |
$1K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
23 |
18 |
$1K |
| H0049 |
Alcohol and/or drug screening |
108 |
98 |
$906.75 |
| 99350 |
Prolong home eval add 15m |
30 |
28 |
$775.25 |
| 99406 |
|
75 |
70 |
$599.70 |
| 99439 |
|
13 |
13 |
$520.84 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
29 |
29 |
$489.32 |
| 90686 |
|
42 |
42 |
$352.44 |
| 99348 |
|
14 |
13 |
$347.83 |
| G0180 |
Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and allowed practitioners to affirm the initial implementation of the plan of care |
439 |
434 |
$282.88 |
| 99345 |
Prolong home eval add 15m |
15 |
13 |
$232.75 |
| 81025 |
|
126 |
89 |
$228.96 |
| G0179 |
Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and allowed practitioners to affirm the initial implementation of the plan of care |
804 |
746 |
$227.61 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
33 |
31 |
$212.68 |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
35 |
23 |
$135.64 |
| 3074F |
|
2,058 |
1,592 |
$125.00 |
| J1071 |
Injection, testosterone cypionate, 1 mg |
164 |
45 |
$120.00 |
| 82962 |
|
108 |
92 |
$83.64 |
| 86580 |
|
22 |
15 |
$66.72 |
| G2012 |
Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion |
18 |
15 |
$35.56 |
| 3077F |
|
2,133 |
1,646 |
$25.00 |
| 81002 |
|
13 |
13 |
$20.27 |
| 4000F |
|
143 |
131 |
$0.00 |
| 1034F |
|
199 |
174 |
$0.00 |
| 3079F |
|
1,252 |
989 |
$0.00 |
| 3080F |
|
1,454 |
1,142 |
$0.00 |
| G8950 |
Elevated or hypertensive blood pressure reading documented, and the indicated follow-up is documented |
227 |
210 |
$0.00 |
| 3075F |
|
518 |
420 |
$0.00 |
| G8420 |
Bmi is documented within normal parameters and no follow-up plan is required |
324 |
252 |
$0.00 |
| 3008F |
|
3,722 |
3,157 |
$0.00 |
| 96415 |
|
37 |
24 |
$0.00 |
| G8419 |
Bmi documented outside normal parameters, no follow-up plan documented, no reason given |
118 |
113 |
$0.00 |
| G0439 |
Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit |
32 |
32 |
$0.00 |
| G8417 |
Bmi is documented above normal parameters and a follow-up plan is documented |
1,151 |
942 |
$0.00 |
| 3078F |
|
2,082 |
1,652 |
$0.00 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
236 |
226 |
$0.00 |
| 3015F |
|
401 |
317 |
$0.00 |
| G8783 |
Normal blood pressure reading documented, follow-up not required |
604 |
551 |
$0.00 |
| 99497 |
|
33 |
27 |
$0.00 |
| G0476 |
Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test |
136 |
81 |
$0.00 |
| 4001F |
|
18 |
16 |
$0.00 |